Chief Information Officer, Sequoia Living. Healthcare Technology & Operations Leader. AgeTech expert. Startup & Venture Capital/Private Equity Advisor.
Rock Health always an interesting read in their annual predictions, and this year's is no different. Practically every company, #healthcare or not, is touting their #AI use, so that's not surprising, and their "maturity curve" looks remarkably similar to Gartner's Adoption Cycle, although they don't use the word "hype". Happy to see a focus on #Foodasmedicine and #precisionmedicine, which is maturing nicely, and not surprised to see #wearables show up...although until battery tech advances more in the next 3-5 years, I think we're still going to see slow adoption. Are there any other areas you found surprising or see differently? I'd love to hear in the comments. #digitalhealth #agetech #AI #precisionmedicine #CIO #aging #seniorliving
Rock Health's annual "predictions" piece is here! (with a twist...) Last year, we created the Rock Health Innovation Maturity Curve as a quantitative, data-driven framework for making our EOY predictions about the commercial progress of emerging markets. This year, we measured where 2023's "hot topics" landed (#AI, digital #obesity care, #foodasmedicine)(spoiler: they all climbed up the maturity curve), and dropped 3 new "hot topics" to watch over the coming year (next-gen #wearable form factors, #phenotyping and #digitaltwins, #climate health). Read on for more! What I'm personally watching over the coming year: #FaM and digital obesity care are rapidly evolving in lock-step. Demand for better, more sustainable results in weight care and more engaging and consumer-friendly care models is meeting a growing supply of FaM companies looking to build early commercial wins by demonstrating cost-savings and sustained behavior change over 12+ mos. Drawing on precedent from the #precisionmedicine landscape may prove useful in shaping winning go-to-market strategies. Companies in these markets should be thinking about modular care pathways that support needs across the care continuum— e.g., FaM as a "first-line therapy" for consumers with low likelihood of benefiting from a #GLP1 (e.g., determined from biomarkers like Phenomix Sciences' obesity phenotyping assay), FaM as a companion solution while on GLP-1s (e.g., Kroger Health's weight management program), or as transitional support solutions used to build lasting healthy behaviors while transitioning off of therapy. https://lnkd.in/g74cYxSK Thanks to my brilliant colleagues Sari Kaganoff Adriana Krasniansky Mihir Somaiya, who put this analysis together!
